MedTrace Logo

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

NCT03256136 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2020-11-04

Study results available
· View outcomes & findings →

Summary

This research study is studying a drug intervention as a possible treatment for lung cancer.

The drugs involved in this study are:

* Nivolumab
* Carboplatin
* Pemetrexed
* Ipilimumab

Conditions

Interventions

DRUG

Carboplatin

Chemotherapy

DRUG

Nivolumab

will allow the body's immune system to work against tumor cells

DRUG

pemetrexed

Chemo therapy

DRUG

Ipilimumab

will allow the body's immune system to work against tumor cells

Sponsors & Collaborators

Principal Investigators

  • Alice Shaw, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-22
Primary Completion
2019-08-19
Completion
2019-08-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03256136 on ClinicalTrials.gov